Urine concentrations of norsalsolinol, N-methyl-norsalsolinol, and salsolinol
| Norsalsolinol | N-methyl-norsalsolinol | Salsolinol | ||||
|---|---|---|---|---|---|---|
| T1 | T2 | T1 | T2 | T1 | T2 | |
| *Six patients died during the follow up period. | ||||||
| Data are given as mean (SD) (range) in nmol/ml. | ||||||
| Control subjects (n = 14) | 0.04 (0.04) (0–0.11) | 0.04 (0.06) (0–0.13) | 0.71 (0.84) (0–2.11) | 0.75 (1.28) (0–3.40) | 0.08 (0.15) (0–0.45) | 0.14 (0.17) (0–0.48) |
| PD patients | ||||||
| Untreated (n = 3) | 0.03 (0.04) (0–0.07) | 0.05 (0.01) (0.03–0.06) | 0.01 (0.01) (0–0.01) | Not detected | 0.11 (0.10) (0.01–0.20) | 0.30 (0.16) (0.14–0.46) |
| Treated, total (n = 44 at T1, 38 at T2*) | 0.51 (1.24) (0–5.93) | 0.18 (0.41) (0–2.18) | 3.31 (4.87) (0.14–18.27) | 2.39 (3.94) (0–15.40) | 1.04 (1.22) (0–6.47) | 0.69 (1.72) (0–9.16) |
| Levodopa dosage | ||||||
| <300 mg/day (n = 15) | 0.45 (1.16) (0–4.75) | 1.28 (0.80) (0.42–2.54) | 0.63 (0.66) (0–2.16) | |||
| 300–600 mg/day (n = 24) | 0.50 (1.30) (0–5.93) | 4.08 (5.92) (0.14–18.27) | 1.21 (1.53) (0–6.47) | |||
| >600 mg/day (n = 5) | 0.55 (0.99) (0–2.31) | 6.09 (5.41) (2.27–9.92) | 1.30 (0.68) (0.39–1.92) | |||